• About Us
  • Our Approach
  • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • Covid-19 mAb
  • News
  • Careers
  • About Us
  • Our Approach
  • Discovery Platform
  • Pipeline
    • HMBD-001
    • HMBD-002
    • Covid-19 mAb
  • News
  • Careers

RATIONAL ANTIBODIES.
REVOLUTIONARY THERAPIES.

Hummingbird Bioscience is on a mission to unravel the complexities of human disease and revolutionize drug discovery to improve treatment outcomes.

Using systems biology and the latest advances in computational methods, we find optimal yet elusive epitopes on validated drug targets and develop innovative biotherapeutics to precisely engage them.

This is a powerful approach to finding new drugs for patients who do not respond to current treatments.

 
Hummingbird Bioscience is on a mission to unravel the complexities of human disease and revolutionize drug discovery to improve treatment outcomes.
Using systems biology and the latest advances in computational methods, we find optimal yet elusive epitopes on validated drug targets and develop innovative biotherapeutics to precisely engage them.
This is a powerful approach to finding new drugs for patients who do not respond to current treatments.

Learn more
about our pipeline
and partners

Latest news

17 December 2020

[BioWorld Interview] Hummingbird taps Tempus’ AI for clinical trial in rare NRG1 fusion patients

14 December 2020

Hummingbird Bioscience announces collaboration with Tempus to harness AI-driven precision medicine to accelerate clinical development of HMBD-001 in HER3 driven cancers including NRG1-fusions.

17 November 2020

Our co-founder and CSO Jerome Boyd-Kirkup speaks with Nancy Hungerford and Tanvir Gill on CNBC Street Signs Asia about Hummingbird’s growing drug discovery and development capabilities, and how they are driving our pipeline of promising therapies for hard to treat conditions, including Covid-19 mAb, an antibody therapy for COVID-19, currently in human trials.

27 October 2020

Hummingbird Bioscience receives clinical trial authorization to initiate a Phase I/II clinical trial for Covid-19 mAb, an anti-SARS-CoV-2 antibody for the treatment of COVID-19. A pre-print paper is published on bioRxiv
JLABS Texas Medical Center
2450 Holcombe Blvd Suite J Houston, TX 77021

Registered Company No:
201505192N
Temasek Lifescience Laboratories
1 Research Link
Singapore 117604
For general enquiries, please contact contact@hummingbirdbio.com

For career enquiries, please contact careers@hummingbirdbio.com
JLABS Texas Medical Center
2450 Holcombe Blvd Suite J
Houston, TX 77021
Temasek Lifescience Laboratories
1 Research Link
Singapore 117604
Registered Company No: 201505192N
For general enquiries, please contact contact@hummingbirdbio.com
For career enquiries, please contact careers@hummingbirdbio.com
PRIVACY POLICY | © 2020 Hummingbird Bioscience
  • About Us
  • Our Approach
  • Discovery Platform
  • Pipeline
    ▼
    • HMBD-001
    • HMBD-002
    • Covid-19 mAb
  • News
  • Careers